ClinicalTrials.gg
CompletedNCT06258980Updated Feb 14, 2024

Use of Recombinant Factor VII as a Prophylactic Therapy for Adolescent Females With Heavy Menstrual Bleeding

An observational study in Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention, sponsored by Minia University Hospital. Completed at 1 site in Egypt. Open to female participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by Minia University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3
Ages
12 Years to 18 Years
Sex
Female
01

Study summary

the study is conducted on adolescent females proved to be Glanzmanns Thrombaesthenia with heavy menstrual bleeding by the use of 3 doses of recombinant factor VII in the first day of their cycles. bleeding profile and quality of life were assessed before and 1year after this regular recombinant factor VII administration.

02

Conditions studied

  • Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention
03

In context

Lead sponsor

Minia University Hospital is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

adolescent females known Glanzmanns Thrombaesthenia with heavy menstrual bleeding

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adolescent females proved to be Glanzmanns Thrombaesthenia heavy menstrual bleeding no improvment by transfusion or antifibrinolytic therapy

Exclusion criteria

Exclusion Criteria:

chronic systemic disease previous allergic reaction to recombinant FVII

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • heavily menstruating females with glanzmannns Thrombaesthenia

    Drug: Proph7

Interventions

  • DrugProph7

    Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females

06

What researchers measure

Primary outcomes

  1. regular accepted menstrual cycles less than 6 days

    Time frame: 1 year

07

Study locations

1 site
  • Gehan Lotfy Abdel Hakeem
    Al Minyā, 61111, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Jan 15, 2023
Primary completionActual
Feb 2, 2024
CompletionActual
Feb 5, 2024
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258980
Lead sponsor
Minia University Hospital
Responsible party
Gehan Lotfy Abdel Hakeem (professor of pediatric hematology, Minia University, Minia University Hospital) — Principal investigator
First posted
Feb 14, 2024
Start date
Jan 15, 2023
Primary completion
Feb 2, 2024
Completion
Feb 5, 2024
Last update
Feb 14, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion